Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects

Area of Science:

• Oncology
• Pharmacology
• Bioinformatics

Background:

• Lung cancer is a leading global malignancy.
• Targeted therapies offer a promising treatment avenue for lung cancers.
• Identifying novel therapeutic targets is crucial for advancing lung cancer treatment.

Purpose of the Study:

• To map the science-technology-clinical development patterns of lung cancer targets.
• To construct a target-target interaction network for identifying novel therapeutic candidates.
• To predict and prioritize potential targets for future lung cancer drug discovery.

Main Methods:

• Classification of cancer targets into three groups.
• Literature, patent, and clinical trial searches for Group 1 and Group 2 targets.
• Construction of a target-target interaction network for Group 1 targets.
• Identification of science-technology-clinical development patterns.
• Prediction of Group 2 targets based on network analysis and development patterns.

Main Results:

• The target-target interaction network for Group 1 revealed three distinct clusters.
• Potential targets in Group 2 were ranked into three priority levels.
• Level-1 targets (16 total), including STAT3, CRKL, and PTPN11, are primarily involved in signaling pathways.
• Level-2 and Level-3 targets comprise 8 and 6 targets, respectively, involved in diverse biological functions.

Conclusions:

• This research provides a framework for lung cancer drug development.
• Prioritization of Level-1 targets is recommended for further investigation.
• The underlying mechanisms of prioritized targets warrant deeper exploration for therapeutic potential.